Evaxion Biotech Completes Final Patient Visit in Phase 2 Extension Trial for Personalized Melanoma Vaccine EVX-01

Evaxion Biotech has completed the final patient visit in the one-year extension phase of its ongoing Phase 2 clinical trial for EVX-01, a personalized cancer vaccine. The company announced this milestone, marking a significant step in its evaluation of the investigational treatment designed to target advanced melanoma.

The Phase 2 trial extension focused on assessing long-term safety and efficacy outcomes of EVX-01, which utilizes artificial intelligence to tailor immunotherapy treatments based on individual patient profiles. The study involved patients with advanced melanoma who had previously undergone standard therapies. Evaxion stated that data collected during this extended period will contribute to understanding the vaccine’s potential benefits and risks over time. Further analysis is expected as researchers review findings from this stage of the trial.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 7, 2026

Author

GOAI